反常性痤疮的生物治疗进展

doi:10.35541/cjd.20200727

Abstract

Abstract: 【Abstract】 With the increasing understanding of inflammatory pathogenesis of acne inversa, as well as with the development and application of biological agents in the treatment of autoimmune inflammatory diseases, some biological agents have shown good efficacy and potential for the treatment of acne inversa in clinical research and practice. This review mainly summarizes the research progress in biotherapy of acne inversa in recent years.

Key words: Hidradenitis suppurativa, Biological agents, Therapy, Acne inversa, Adalimumab, Infliximab

Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa[J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.doi:10.35541/cjd.20200727

References ［28］

［1］	Ingram JR, Jenkins⁃Jones S, Knipe DW, et al. Population⁃based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa［J］. Br J Dermatol, 2018,178（4）:917⁃924. doi: 10.1111/bjd.16101.
［2］	Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population［J］. Arch Dermatol Res, 2021,313（2）:95⁃99. doi: 10. 1007/s00403⁃020⁃02065⁃2.
［3］	Sandhu VK, Shah M, Piguet V, et al. The impact of hidradenitis suppurativa on work productivity and activity impairment［J］. Br J Dermatol, 2020,182（5）:1288⁃1290. doi: 10.1111/bjd.18695.
［4］	中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:97⁃104. doi: 10.35541/cjd.20200802.
［5］	Kimball AB, Tzellos T, Calimlim BM, et al. Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient⁃reported outcomes: post hoc analysis of pooled data from PIONEER I and II［J］. Acta Derm Venereol, 2018,98（10）:932⁃937. doi: 10.2340/00015555⁃3012.
［6］	Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890.
［7］	Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa［J］. N Engl J Med, 2016,375（5）:422⁃434. doi: 10.1056/NEJMoa1504370.
［8］	Zouboulis CC, Okun MM, Prens EP, et al. Long⁃term adalimumab efficacy in patients with moderate⁃to⁃severe hidradenitis suppurativa/acne inversa: 3⁃year results of a phase 3 open⁃label extension study［J］. J Am Acad Dermatol, 2019,80（1）:60⁃69. doi: 10.1016/j.jaad.2018.05.040.
［9］	Caposiena Caro RD, Cannizzaro MV, Tartaglia C, et al. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab［J］. Clin Exp Dermatol, 2020,45（4）:438⁃444. doi: 10.1111/ced.14127.
［10］	Salvador⁃Rodriguez L, Montero⁃Vílchez T, Arias⁃Santiago S, et al. Paradoxical hidradenitis suppurativa in patients receiving TNF⁃α inhibitors: case series, systematic review, and case meta⁃analysis［J］. Dermatology, 2020,236（4）:307⁃313. doi: 10.1159/000506074.
［11］	Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050.
［12］	Mekkes JR, Bos JD. Long⁃term efficacy of a single course of infliximab in hidradenitis suppurativa［J］. Br J Dermatol, 2008,158（2）:370⁃374. doi: 10.1111/j.1365⁃2133.2007.08332.x.
［13］	Paradela S, Rodríguez⁃Lojo R, Fernández⁃Torres R, et al. Long⁃term efficacy of infliximab in hidradenitis suppurativa［J］. J Dermatolog Treat, 2012,23（4）:278⁃283. doi: 10.3109/09546634. 2012.683767.
［14］	Brunasso AM, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor⁃alpha inhibitors: an update on infliximab［J］. Acta Derm Venereol, 2011,91（1）:70⁃71. doi: 10.2340/00015555⁃0989.
［15］	Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa［J］. J Am Acad Dermatol, 2019,81（3）:702⁃708. doi: 10.1016/j.jaad. 2019.05.022.
［16］	Vural S, Gündoğdu M, Akay BN, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy［J］. Dermatol Ther, 2019,32（5）:e13003. doi: 10.1111/dth.13003.
［17］	Giamarellos⁃Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open⁃label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa［J］. Br J Dermatol, 2008,158（3）:567⁃572. doi: 10.1111/j.1365⁃2133.2007. 08372.x.
［18］	Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa［J］. Br J Dermatol, 2006,154（4）:726⁃729. doi: 10.1111/j.1365⁃2133.2005.07067.x.
［19］	Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum［J］. Br J Dermatol, 2016,174（4）:839⁃846. doi: 10. 1111/bjd.14338.
［20］	Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:e140⁃140e141. doi: 10.1111/jdv.15368.
［21］	Montero⁃Vilchez T, Martinez⁃Lopez A, Salvador⁃Rodriguez L, et al. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review［J］. Dermatol Ther, 2020,33（3）:e13456. doi: 10.1111/dth.13456.
［22］	Leslie KS, Tripathi SV, Nguyen TV, et al. An open⁃label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa［J］. J Am Acad Dermatol, 2014,70（2）:243⁃251. doi: 10.1016/j.jaad.2013.09.044.
［23］	Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial［J］. JAMA Dermatol, 2016,152（1）:52⁃59. doi: 10. 1001/jamadermatol.2015.3903.
［24］	André R, Marescassier H, Gabay C, et al. Long⁃term therapy with anakinra in hidradenitis suppurativa in three patients［J］. Int J Dermatol, 2019,58（11）:e208⁃e209. doi: 10.1111/ijd.14596.
［25］	Prussick L, Rothstein B, Joshipura D, et al. Open⁃label, investigator⁃initiated, single⁃site exploratory trial evaluating secukinumab, an anti⁃interleukin⁃17A monoclonal antibody, for patients with moderate⁃to⁃severe hidradenitis suppurativa［J］. Br J Dermatol, 2019,181（3）:609⁃611. doi: 10.1111/bjd.17822.
［26］	Thorlacius L, Theut Riis P, Jemec G. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report［J］. Br J Dermatol, 2018,179（1）:182⁃185. doi: 10.1111/bjd.15769.
［27］	Schuch A, Fischer T, Boehner A, et al. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin⁃17a antibody secukinumab［J］. Acta Derm Venereol, 2018,98（1）:151⁃152. doi: 10.2340/00015555⁃2794.
［28］	Giamarellos⁃Bourboulis E, Argyropoulou M, Kanni T, et al. Efficacy and safety of IFX⁃1, an anti⁃C5a monoclonal antibody in an open label Phase 2a study in patients with severe hidradenitis suppurativa （HS） not eligible for adalimumab［R］// Special Issue: Abstracts of the 7th European Hidradenitis Suppurativa Foundation （EHSF） Congress, Rotterdam, The Netherlands. Exp Dermatol, 2018,27（S1）: 5⁃32.doi: 10.1111/exd.13538.

[1]	Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220140-e20220140.
[2]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[4]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[5]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[6]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[7]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220337-e20220337.
[8]	Tian Jing, Liang Yuan, Ma Lin. Dupilumab in the treatment of childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210730-e20210730.
[9]	Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.
[10]	Peng Ying, Liu Yi. Medications for the treatment of acne [J]. Chinese Journal of Dermatology, 2023, 56(2): 173-176.
[11]	Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210536-e20210536.
[12]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[13]	Jia Yuanyuan, Mao Qiuyu, Yang Jingyi, Min Wei. Efficacy of dupilumab in the treatment of moderate and severe atopic dermatitis in the elderly: a clinical observation [J]. Chinese Journal of Dermatology, 2023, 56(2): 125-129.
[14]	Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology, The Dermatology Branch of Chinese Medical Education Association. Expert consensus on diagnosis and treatment of senile herpes zoster [J]. Chinese Journal of Dermatology, 2023, 56(2): 97-104.
[15]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210803-e20210803.

Biotherapy for acne inversa

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［28］

Related Articles 15

Metrics

Comments

Recommended 10